Literature DB >> 24049916

In vitro action of combinations of antimicrobial agents with EDTA-tromethamine on Proteus vulgaris of a canine origin.

R E Wooley1, M S Jones, J P Gilbert, E B Shotts.   

Abstract

Combinations of EDTA-tromethamine and 7 antimicrobial agents (chloramphenicol, nalidixic acid, oxytetracycline, penicillin, polymyxin-B, streptomycin, or a combination of sulfamethazine, sulfapyridine, and sulfathiazole) were tested for synergistic activities against Proteus vulgaris of canine origin. Three in vitro tests were used, including minimal inhibitory concentrations of the drugs, a 2-dimensional microtiter checkerboard technique, and bacterial inhibition studies. A synergistic inhibitory action was observed with combinations of EDTA-tromethamine plus penicillin, oxytetracycline, nalidixic acid, chloramphenicol, polymyxin-B, or sulfamethazine-sulfapyridine-sulfathiazole by at least one test system. A synergistic effect was not recorded with combinations of EDTA-tromethamine and streptomycin. Poor correlation between data from the 3 test systems was noticed, despite the fact that each monitors bacteriostatic end points.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 24049916

Source DB:  PubMed          Journal:  Am J Vet Res        ISSN: 0002-9645            Impact factor:   1.156


  3 in total

1.  Potentiation of the in vitro activity of some antimicrobial agents against selected gram-negative bacteria by EDTA-tromethamine.

Authors:  A M Farca; P Nebbia; G Re
Journal:  Vet Res Commun       Date:  1993       Impact factor: 2.459

2.  Antimicrobial effect of combinations of EDTA-Tris and amikacin or neomycin on the microorganisms associated with otitis externa in dogs.

Authors:  T A Sparks; D T Kemp; R E Wooley; P S Gibbs
Journal:  Vet Res Commun       Date:  1994       Impact factor: 2.459

3.  Potentiation of antibiotic activity by EDTA-tromethamine against three clinically isolated gram-positive resistant bacteria. An in vitro investigation.

Authors:  A M Farca; P Nebbia; G Re
Journal:  Vet Res Commun       Date:  1994       Impact factor: 2.459

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.